Eli Lilly and Company (LLY) on Monday announced positive topline results from the Phase 3 BRUIN CLL-322 study evaluating Jaypirca in combination with venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The study met its primary endpoint, showing that adding Jaypirca to venetoclax and rituximab significantly improved progression-free survival compared with the standard combination, as assessed by an independent review committee. The benefit was consistent across key patient subgroups, including those previously treated with a covalent BTK inhibitor.
The safety profile of the combination was in line with the known safety of the individual medicines.
Lilly said it plans to submit the data to regulators later this year to seek an expansion of Jaypirca's label.
Jaypirca is currently approved for treating adult patients with relapsed or refractory CLL or SLL who have previously received a covalent BTK inhibitor, as well as for relapsed or refractory mantle cell lymphoma after at least two prior lines of therapy, including a BTK inhibitor, under accelerated approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.